Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients

Serum Magnesium and Outcomes in Heart Failure With Reduced Ejection Fraction: The GALACTIC-HF Trial

Evaluation of Aficamten or Beta-Blocker Monotherapy Versus Placebo in Patients with Obstructive Hypertrophic Cardiomyopathy: A Pooled Analysis of SEQUOIA-HCM and MAPLE-HCM

Electrocardiographic Changes and Associations with Echocardiographic Changes in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial

Aficamten Versus Metoprolol in Patients with Hypertension and Obstructive Hypertrophic Cardiomyopathy

Clinical Implications Associated With Temporary Treatment Interruption and Reinitiation of Aficamten Therapy in Obstructive Hypertrophic Cardiomyopathy

Effect of the Cardiac Myosin Activator Omecamtiv Mecarbil on Ventricular Arrhythmias, Cardiac Arrest, and Sudden Death in Heart Failure With Reduced Ejection Fraction: The GALACTIC-HF Trial

Mitral Regurgitation in Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF

Clinical Evaluation of Drug-Drug Interactions With Aficamten

Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM Long-Term Study